$49.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
PEG MGF 2mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
PEG MGF 2mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 108174-48-7 |
|---|---|
| Purity | ≥99% |
| Sequence | PEG-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-NH2 |
| Molecular Formula | C121H200N42O39 |
| Molecular Weight | 2 867 g/mol |
| Applications | Muscle hypertrophy research, tissue regeneration studies, satellite-cell activation investigations |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
For qualified laboratory teams, the search phrase “buy peg mgf” should be reframed as buy PEG-MGF for research, with the focus on compound identity, COA review, analytical testing, and RUO labeling. PEG-MGF refers to a PEG-modified mechano growth factor research peptide, while MGF is discussed in the literature as an IGF-1-related splice-variant and E-domain peptide research topic [1] [5] [18]. This page keeps Pure Lab Peptides product-page content separate from product claims and limits the discussion to published literature, documentation review, and research procurement.
Researchers looking to buy PEG-MGF for research should first verify that the listing is RUO-labeled, supported by batch-specific COA documentation, and aligned with identity and purity testing records. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Literature can inform context; procurement review should prioritize analytical data, lot traceability, and supplier documentation [22] [24].
Commercial research intent is safest when it becomes a documentation workflow. Instead of treating “buy PEG-MGF” as a standalone purchase phrase, research teams should evaluate whether the product page, label, COA, and testing records describe the same PEG-MGF peptide.
This keeps the query in a research and laboratory context. It also helps separate procurement review from literature claims, unsupported outcome language, or non-RUO framing.
A certificate of analysis should be reviewed for compound name, lot number, test date, method type, purity result, and identity-supporting data. Analytical validation guidance emphasizes that test procedures should be fit for their intended analytical purpose, which is relevant when researchers interpret COA fields such as identity, purity, and assay method [22].
The strongest review starts by asking whether the COA belongs to the specific batch being evaluated. A generic document is less useful than a batch-specific record that matches the research material listing.
RUO labeling signals that the material is positioned for laboratory research rather than diagnostic or consumer application. FDA’s RUO guidance for IVD products explains that RUO labeling must align with the manufacturer’s intended research positioning, and 21 CFR 809.10 contains the familiar RUO label language for laboratory research-phase IVD products [29] [30].
Pure Lab Peptides applies the same conservative editorial principle here: research pages should keep intended-use language narrow, clear, and documentation-led.
PEG-MGF is commonly described as a PEGylated mechano growth factor research peptide. MGF itself is associated with IGF-1-related splice-variant literature, while PEGylation refers to covalent modification with polyethylene glycol or related PEG chemistry [5] [18] [19].
Researchers should avoid assuming that every catalog listing, literature peptide, or database record represents the same material. Exact identity depends on the listed compound, sequence or modification data, molecular weight, and batch documentation.
The IGF1 gene is a protein-coding gene with multiple transcript variants, and official NCBI records identify “mechano growth factor” among IGF1-associated names [1]. UniProt describes IGF-1 as an insulin-like growth factor protein, while PubChem includes a mechano growth factor compound record that can support high-level identity orientation, not batch-specific verification [2] [4].
For a PEG-MGF peptide listing, the practical research question is not only “what is MGF?” It is whether the supplied research material is documented as PEG-MGF with consistent identity, purity, and lot-level records.
MGF is discussed in the literature as an IGF-1-related splice-variant topic, often connected with IGF-1Ec terminology in human literature and related isoform naming in model-specific research [5] [6]. Reviews also caution that IGF1 gene splicing, post-translational processing, and peptide bioactivity are complex and should not be collapsed into one simplified product claim [7].
That distinction matters for SEO and compliance. A product page can describe literature context, but it should not imply that a catalog material reproduces every finding from every IGF-1 or MGF paper.
PEGylation can alter the size, chromatographic behavior, and characterization requirements of a peptide or protein conjugate [18] [19]. Reviews of PEG-modified biomolecules also describe how PEG structure, attachment site, and molecular-weight distribution can influence analytical characterization [20] [21].
For PEG-MGF research, this means documentation should not stop at the name “MGF.” The PEG component, stated identity method, and lot-specific analytical data should be part of the review.
A PEG-MGF peptide listing should function as a research material entry. The listing can identify the catalog compound, but the COA and supporting records should confirm how that material is characterized.
The safest product-page architecture treats PEG-MGF as the canonical entity. Product amounts such as PEG-MGF 2mg or 5mg are catalog specifications, not separate SEO targets and not product-use instructions.
A clear research material listing should identify the compound name, research-only status, available documentation, and relevant testing records. It should avoid unsupported product effects or product performance language and keep the content focused on COA review, analytical verification, and lot traceability.
When the listing says “available for research,” the next question is evidence quality. Researchers should compare the listing against the COA and label rather than relying on the product title alone.
The phrase buy PEG-MGF for research belongs in supplier evaluation, not consumer guidance. A technical procurement team can use the phrase to locate a research peptide, then judge the supplier by documentation quality, not by broad claims.
This is also where Pure Lab Peptides’ product-page content should be most useful. It should help researchers decide whether the documentation is complete enough for laboratory review.
Catalog amounts such as 2mg and 5mg can help identify a listing, but they should remain neutral catalog details. They should not create separate variant pages, separate commercial intent, or instructional language.
For SEO, PEG-MGF stays the canonical compound. The article can acknowledge catalog specifications without turning them into separate product-positioning themes.
A PEG-MGF for sale page should answer research procurement questions. It should clarify documentation, testing, label consistency, and literature boundaries without drifting into personal-use or outcome-focused language.
That approach also helps commercial intent remain compliant. Search phrases such as PEG-MGF for sale, PEG-MGF for sale online, sale online, and buy PEG-MGF online should be interpreted as research-supplier evaluation queries.
Online search behavior can be broad, but the page should narrow it. Research buyers evaluating PEG-MGF for sale online should find RUO labeling, COA availability, analytical testing context, and supplier documentation expectations.
This protects the page from unsafe commercial framing. It also gives qualified researchers the practical information needed to assess a research material listing.
Listing language should start with what can be documented: compound name, PEGylated mechano growth factor identity, batch information, purity method, identity method, label status, and storage documentation. It should avoid turning mechanistic literature into claims about a product.
A useful rule is simple. If a sentence cannot be supported by the product documentation or a cited research source, it should not be presented as product-page substance.
Research buyers should compare the product-page listing, COA, label, batch number, method description, and storage notes. If those records conflict, the documentation review should pause.
A practical supplier review should also consider whether the product page avoids unsupported claims. For procurement teams, clean documentation is more useful than broad marketing language.
Mechano growth factor literature sits inside a broader IGF-1 research context. Early work by Goldspink-associated groups examined IGF-1 splice variants in mechanically stimulated skeletal muscle models, and later reviews debated how synthetic MGF peptides relate to IGF1 gene products [5] [8] [9].
For a product page, this background should be concise. The purpose is to orient researchers, not to convert model findings into product positioning.
Pegylated mechano growth factor combines two research ideas: an MGF peptide context and PEG modification chemistry. PEGylation has a large analytical literature because PEG conjugation can change characterization requirements for peptide and protein materials [18] [21].
That does not mean every PEG-MGF listing has the same research profile. The page should keep the literature overview separate from the exact batch being reviewed.
The E-domain discussion is context-sensitive because the literature includes IGF-1 isoforms, propeptide regions, synthetic peptides, and model-specific assays [7] [11]. A paper that examines one MGF E peptide in one model does not automatically define all PEG-MGF research materials.
This is why “growth factor E peptide” language needs careful framing. It can describe a literature category, but it should not become a product claim.
Published findings are not uniform across models. For example, Kandalla and colleagues reported MGF-E peptide activity in human muscle progenitor cell models, while Fornaro and colleagues reported no apparent activity in myoblasts or primary muscle stem cells under their study conditions [11] [12].
That contrast is valuable. It shows why PEG-MGF research content should discuss scope, model, and limitations instead of using one paper as a universal statement.
Skeletal muscle appears in MGF literature because researchers have studied IGF-1 splice variants and MGF-related transcripts in muscle model systems [8] [9]. The product page can reference skeletal muscle research context without implying a catalog material produces any outcome.
The core boundary is model specificity. Research relevance is not the same thing as product performance.
Cell models help researchers isolate variables such as cell type, peptide form, pathway readout, and assay condition. MGF-E peptide literature includes work in muscle progenitor cells and mesenchymal stem cells, which supports a research-context discussion of migration, differentiation, and model-specific cellular responses [11] [13].
This should stay in the language of model investigation. It should not become a claim about PEG-MGF as a product.
Satellite cells are often described as skeletal muscle stem cells, and reviews explain their role in the muscle stem cell niche and skeletal muscle research models [16] [17]. MGF literature sometimes intersects with satellite cell activation and muscle cell model discussions [5].
The caution is that satellite cell literature is not a procurement claim. It is a topic area that requires model, source, and assay context.
Pathway context explains what researchers have examined. It does not say what a research material will do in a different model or setting.
For PEG MGF research, pathway language should stay tied to cited studies, receptor-assay data, or analytical documentation. That boundary keeps the page useful and RUO-safe.
Published literature has examined IGF1 splice variants, IGF-1Ec/MGF terminology, MGF peptide models, and receptor-related questions [5] [6] [14]. NCBI and UniProt records support the broader IGF1 and IGF1R identity context, but they do not replace batch-specific peptide verification [1] [2] [3].
The safest interpretation is layered. Gene, protein, peptide, PEG-modified compound, and catalog batch are related documentation layers, not interchangeable terms.
Research findings describe what was examined under defined study conditions. Product positioning describes what the page says about a research material.
Those two layers must remain separate. If a paper reports a model-specific finding, the product page can cite it as literature context, but it should not use it as a claim for a PEG-MGF listing.
In vitro and preclinical models can clarify pathway questions, cell-model responses, transcript context, and assay-dependent differences [9] [11] [12]. They can also show disagreements across methods, which is useful for evidence interpretation.
Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
Citation quality matters because PEG-MGF search results can mix academic sources, vendor pages, forums, and marketing summaries. Product-page content should prioritize peer-reviewed literature, official databases, and recognized analytical guidance.
A safe source-quality filter is: official database first for identity, peer-reviewed study for model claims, analytical guidance for testing language, and supplier documentation for batch-specific review.
The evidence landscape should be read from narrow to broad: database identity, mechanistic or cell-model literature, analytical method literature, and batch-specific documentation. This prevents a single claim type from doing too much work.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| IGF1 and MGF nomenclature | IGF1 records and MGF review literature describe transcript and isoform context [1] [5] | Official database, review | Supports naming context, not batch identity |
| Mechanical-stimulus models | Early studies examined IGF-1 splice variants in skeletal muscle model systems [8] [9] | Experimental literature | Model-specific research context only |
| Cell-model research | MGF-E peptide papers report model-dependent observations in progenitor or stem cell systems [11] [13] | Cell-model literature | Describes study findings, not product claims |
| Receptor context | Full-length MGF has been studied in IGF-1 receptor activation assays [3] [14] | Receptor assay | Supports pathway context only |
| Analytical verification | HPLC, LC-MS, and mass spectrometry support peptide purity and identity review [25] [26] [28] | Analytical literature | Supports documentation review |
Study scope should stay attached to the model, method, and source. Supplier copy should focus on what can be documented for the research material: identity, purity, lot number, COA, label, and testing method.
A useful internal question is: “Would this sentence still be accurate if the cited study and the product batch were reviewed separately?” If the answer is no, the sentence needs narrower framing.
Literature limitations include model type, peptide form, species or cell-line context, assay endpoint, and whether the paper studied full-length MGF, an MGF E peptide, or another IGF-1-related construct. Reviews of IGF1 splicing emphasize that isoform biology and post-translational processing are complex, so simplified claims should be avoided [7].
A good PEG-MGF research page should state what the literature can show and what it cannot show. That balance builds trust without turning the page into a claim-heavy article.
Research literature belongs in a literature-context layer. Product claims belong to product positioning, and RUO product pages should avoid using model-specific findings as claims.
Phrases about product effects, product performance, or clinical-use language can turn a literature summary into a claim if they are separated from study context. This article keeps those phrases tied to boundaries, documentation, and RUO interpretation.
Study language can include pathway activity, cell-model findings, and assay observations. Listing language should describe the research material and documentation available for review.
That means a PEG-MGF listing can mention published literature, but it should not imply that the catalog material has the same scope as a paper’s experimental conditions. The safer page structure keeps the claim boundary visible.
RUO copy should answer documentation questions first. What is the compound name? Is there a COA? What methods support purity and identity? Does the lot number match?
This approach serves commercial research intent without drifting into consumer-facing claims. It also gives procurement teams a clear path for technical review.
A certificate of analysis matters because it connects the product-page listing to a batch-specific quality record. For PEG-MGF, the COA should help research buyers confirm that the listed peptide, lot number, and analytical results are aligned.
Analytical guidance from ICH and FDA supports the broader principle that identity, purity, method suitability, and documented data matter when evaluating analytical records [22] [24].
A batch-specific COA should confirm the compound name, lot number, test method, result date, and reported analytical findings. For peptide materials, the COA is most useful when purity data and identity-supporting data can be connected to the same lot.
A COA should not be treated as a decorative document. It should be a reviewable record that supports research procurement decisions.
Purity, identity, and lot data answer different questions. Purity asks how much of the detected material aligns with the main component under a stated method, while identity asks whether the detected material is consistent with the intended peptide [25] [28].
Lot data connects those results to the exact batch. Without lot traceability, even strong analytical data can be hard to apply to a specific research material.
Analytical testing workflow should be documentation-focused. The goal is to check whether the COA, label, and testing records support the same PEG-MGF peptide identity.
Use this lab-test verification workflow for documentation review:
HPLC is widely used in peptide analysis because it separates peptide components and can support purity assessment under defined chromatographic conditions [25]. For PEG-MGF, HPLC data should be read with the method, chromatogram, retention time, and batch record in view.
HPLC is strongest when paired with clear documentation. A purity percentage by itself does not answer every identity question.
LC-MS and related mass spectrometry methods can support identity review by connecting chromatographic separation with mass-based information [26] [27]. Mass spectrometry is especially relevant for synthetic peptide characterization because it can evaluate authenticity and integrity when the expected sequence or molecular identity is known [28].
For PEGylated materials, documentation should also account for PEG-related analytical complexity. PEG chemistry can affect characterization strategy and should not be ignored [19] [21].
Lot traceability connects the physical research material to the documentation package. Without lot-level alignment, a COA may not prove that the record belongs to the material being evaluated.
A strong documentation package should make the story easy to follow: product listing, label, lot number, COA, analytical method, and storage notes.
Lot numbers matter because research reproducibility depends on knowing which material was reviewed, received, stored, and documented. A lot number can help connect the product-page listing to the batch-specific COA and internal laboratory records.
For PEG-MGF research procurement, lot traceability is not a minor administrative detail. It is the thread that connects supplier documentation to laboratory recordkeeping.
Labeling consistency helps confirm that the listing, container label, COA, and supplier documentation all refer to the same PEG-MGF material. If the product name, amount specification, or lot number differs across records, the discrepancy should be resolved before procurement review continues.
Consistent labeling also supports RUO positioning. It keeps the product page aligned with research-only intent and documentation expectations.
Many research peptides are supplied as lyophilized materials, and storage conditions can affect documentation expectations. Peptide stability can depend on sequence, container type, moisture exposure, and storage environment [31] [32].
For PEG-MGF, the product page should not provide personal-use handling guidance. It should direct research teams to supplier documentation and laboratory recordkeeping.
Freeze-dried materials should be documented with storage conditions, lot number, label status, COA date, and any supplier-provided handling notes. Literature on peptide storage shows that container choice and peptide properties can affect recovery in mass spectrometry-based workflows [31].
The product page should keep this information neutral. The goal is documentation continuity, not practical consumer guidance.
Handling records support research continuity when they show how the material was received, logged, stored, and matched to a lot-specific COA. These records can also help technical teams compare PEG-MGF research materials across suppliers.
A simple quality and documentation checklist can help:
Before researchers buy PEG-MGF for research, the final review should be documentation-led. The listing should be RUO-safe, the COA should be batch-specific, the identity and purity methods should be clear, and the lot number should match supplier records.
Common misunderstandings to avoid:
Review should pause when the product name, lot number, COA, label, or testing record does not align. It should also pause if the product page relies on broad claims rather than research documentation.
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Pure Lab Peptides positions PEG-MGF as a research-use-only peptide material supported by documentation-focused product information. The emphasis belongs on COA availability, analytical testing review, lot traceability, labeling consistency, and responsible laboratory procurement.
For research teams comparing peptide suppliers, prioritize COA availability, transparent labeling, and lot-level documentation before evaluating any research-use-only peptide.
Research use only means PEG-MGF is intended solely for controlled laboratory research purposes. In a product-page context, RUO framing keeps attention on compound characterization, batch documentation, COA review, analytical testing, and supplier records. It does not support consumer positioning or product claims beyond research documentation.
Researchers should consider whether PEG-MGF documentation is complete, batch-specific, and consistent across the product listing, label, COA, and supplier records. A documentation-first review should compare peptide identity, assay purity, lot traceability, storage notes, and available analytical testing. The commercial query should remain a research procurement question.
Published literature about PEG-MGF should be interpreted as research context, not product-positioning language. Literature may discuss insulin-like growth factor-1, an isoform of IGF-1, or a variant of IGF-1 in model-specific settings, but those findings should stay separate from supplier documentation and RUO product-page claims [1] [5].
A COA matters because it helps connect PEG-MGF identity, assay purity, lot traceability, and batch documentation. Researchers should review whether the COA matches the product listing and whether purity or identity data are supported by appropriate analytical testing. A COA is strongest when it is batch-specific rather than generic.
Peptide sequence can support PEG-MGF documentation when it is verified through reliable supplier records or authoritative literature. Sequence information should be treated as part of compound characterization, alongside molecular identity, PEG modification details, and batch documentation. If sequence details are not available, researchers should avoid filling gaps with assumptions.
HPLC, LC-MS, and third-party testing can support PEG-MGF review by adding method-level evidence for purity and identity. HPLC is commonly used for peptide purity review, while LC-MS can support peptide identity when paired with suitable reference data and batch records [25] [26]. These methods support documentation review, not product claims.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: UT Health San Antonio Publication Profile
Martin L. Adamo’s publications are relevant to PEG-MGF research because they address the IGF-I gene, its regulatory context, and how MGF is discussed as a putative IGF-I gene-expression topic. His work helps frame why a PEG-MGF product page should distinguish published literature from batch-level research compound documentation. That distinction is useful when readers compare official gene records, review literature, and product documentation. It also supports a cautious pathway research approach in which IGF-I terminology, splice-variant discussion, and synthetic peptide references stay separate from COA review, lot-level records, and analytical testing.
Selected publications:
Author profile: University of Portsmouth Research Profile
Dariusz C. Górecki’s publications are relevant to the MGF research lane because they address IGF-1 isoform terminology, alternative splicing, and model-specific interpretation across the published literature. His work provides useful context for understanding why MGF references should be read through peptide identity, protein isoform language, and literature boundaries. For a PEG-MGF research page, that context supports careful separation between research model discussion and supplier documentation. It also reinforces why receptor signaling language should be framed as scientific background rather than product-positioning language.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around PEG-MGF, mechano-growth factor, and insulin-like growth factor 1 context. In Growth Factor Peptide and Cellular Pathway Research content, terms such as muscle growth, hypertrophy, muscle injuries, damaged muscle, repair and regeneration, healing, clinical outcomes, and wellness language can drift into consumer-facing or product-claim language when framed incorrectly. They should be read here only as boundary-sensitive language categories, not as product positioning.
The same care applies to therapeutic language, administration-focused language, bioavailability, absorption, immune response, inflammation, and cell death when those terms appear in broader research discussions. On this page, those phrases remain separate from product claims, intended outcomes, personal-use guidance, and product-performance claims. The focus stays on PEG-MGF identity, COA review, analytical testing, peptide purity, lot traceability, research-use-only labeling, product documentation, and published literature boundaries.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.